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THE USE of gut sterilization in a protected environment has been under investigation for several years as a means of reducing infection in patients with cancer undergoing intensive chemotherapy (Bodey et al., 1971; Levine et al., 1973; Yates and Holland, 1973) . The possible effect of the gut sterilizing regimen on the pharmacokinetics of the cancer chemotherapeutic agents being used in these patients is clearly a matter of some importance but has not hitherto been explored. We report observations on the plasma decay of radioactivity in patients who received tritium-labelled methotrexate ([3H]MTX) while on such a regimen, which indicate a possible alteration in the pharmacokinetics of this drug in these patients.
Nine patients were studied, each twice, once before and once during treatment with prophylactic non-absorbable antibiotics (PNAA). All patients had small-cell carcinoma of the lung. They had normal renal and hepatic function, were free of clinical infections and had had no prior radio-or chemotherapy. All gave written informed consent for entry into the study. Five (Creaven et al., 1973) . All urine passed in the 72 h after drug administration was collected as passed, immediately frozen, and the radioactivity determined by counting 0KI ml of an appropriately diluted sample in the same way as for plasma. Patients received MTX twice weekly, chloroethylcyclohexylnitrosourea (CCNU) (100 mg/M2 orally every 6 weeks) and cyclophosphamide (1 g/m2 i.v. every 3 weeks). However, the dose of MTX studied was in each case given by itself. PNAA consisted of polymyxin B 100 mg, paromomycin 800 mg, mycostatin suspension 800,000 u, vancomycin 500 mg and nystatin tablets 3 million u. All were given 4 x daily orally. Polymyxin B, vancomycin, nystatin and neomycin were used in nasal and oral spray, in addition to oral administration. Nonlinear least squares regression analysis of the data was carried out using the programme MLAB on a DEC system 10 computer (Knott and Reece, 1972; Knott and Schrager, 1972) .
Absorption of MTX after oral dosage, both before and during treatment with PNAA, was rapid, the absorptive phase being complete by 2 h. However, absorption was markedly depressed during PNAA treatment; total urinary recovery of 3H being 75-7 ± 10.6% before PNAA, and 41-1 + 10-7% during PNAA treatment, in these 5 patients, a difference significant at the P < 0 001 level. The post-absorptive plasma decay during treatment with PNAA showed an absence of the long terminal phase half-life in all cases (Fig. 1) . Analysis of the postabsorptive phase by non-linear least squares regression showed that before PNAA treatment it fitted the bi-exponential equation
Cp =Ae-,x + Be-fl (1) whereas during PNAA treatment it fitted the mono-exponential equation
Cp =Ae-t
The parameters derived by fitting the data to equation (1) and equation (2) are given in the Table. When the drug was given i.v., PNAA treatment did not significantly alter the post-distributional plasma decay kinetics (Fig. 2, Table) . The half-life of the terminal phase of the plasma decay was, however, considerably shorter after i.v. than after oral dosage.
The Leme et al., 1975) and is confirmed in the present study. We have previously suggested that this long halflife material cannot be MTX itself, since it behaves kinetically in a way which is distinct from MTX (Leme et al., 1975) in the bile, and then reabsorbed. In rats and mice, MTX is degraded by intestinal bacteria (Zaharko and Oliverio, 1970; Valerino et al., 1972) , and a divergence in the plasma decay curves of total radioactivity and unchanged MTX is seen at 6 h post-infusion of [3H]MTX (Kates and Tozer, 1973) . A change in the metabolism and excretion of MTX in mice treated with neomycin and sulphathiazole to sterilize the gut, has been reported by Zaharko, Bruckner and Oliverio (1969) . However, if the long half-life material is a bacterial breakdown product and is absent during PNAA treatment after oral administration of [3H]MTX because ofthe absence of gut bacteria necessary for its formation, it is difficult to understand why it is not also absent during PNAA treatment when the drug is given i.v. Unfortunately, the very low amounts of radioactivity in the samples at later times after dosage precluded chromatographic separation and isolation of this material for identification.
The same difficulty arises if one wishes to postulate failure of absorption, interfering with enterohepatic recycling, as the basis for the difference seen in the present study. The absorption of MTX is impaired during PNAA treatment (Table) as part of a general malabsorption as we have noted previously (Cohen et al., 1975 
